Review
Open access
Oct 2026
Dapagliflozin and empagliflozin versus placebo for cardiovascular death or worsening heart failure across the ejection-fraction spectrum: a systematic review and meta-analysis of randomized placebo-controlled trials
Background and aims: Dapagliflozin and empagliflozin are established therapy for chronic heart failure across the ejection-fraction spectrum. Their pivotal trials were powered for a composite of cardiovascular death and worsening heart failure
Nawaf AM Alharbi, Abdullah Ahmed Alfllaj, Mohamed Ghaith et al.
· International Journal of Dru... · 0 citations